ADX 10059

Drug Profile

ADX 10059

Alternative Names: ADX-10059

Latest Information Update: 18 Dec 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Addex Pharmaceuticals
  • Class Anxiolytics; Small molecules
  • Mechanism of Action Metabotropic glutamate receptor 5 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Anxiety disorders; Drug-induced dyskinesia; Gastro-oesophageal reflux; Migraine; Parkinson's disease

Most Recent Events

  • 15 Dec 2009 Discontinued - Phase-II for Gastro-oesophageal reflux in European Union (PO)
  • 15 Dec 2009 Discontinued - Phase-II for Gastro-oesophageal reflux in USA (PO)
  • 15 Dec 2009 Discontinued - Phase-II for Migraine in European Union (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top